Agenus FCF par action

Que fait Agenus ? Agenus Inc, listed under the ticker AGEN, is a biotechnology company based in Lexington, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Agenus Inc has a workforce of 81 employees. It went public through an IPO on February 4, 2000. The company's website is http://agenusbio.com/. Agenus Inc is engaged in the development of technologies aimed at treating cancers and infectious diseases. The company focuses on therapies that harness the immune system to combat cancer. Agenus Inc's activities include the development of antibody discovery platforms, such as Retrocyte Display, SECANT yeast display, and phage display technologies, which are used to create human antibodies. Additionally, the company is involved in the development of vaccine programs, including Prophage, AutoSynVax, and PhosPhoSynVax, as well as saponin-based vaccine adjuvants, notably QS-21 Stimulon. The company's discovery pipeline features checkpoint modulating (CPM) antibodies. Agenus Inc also works with heat shock protein (HSP)-based Prophage vaccine candidates and synthetic vaccine candidates, such as ASV and PSV. The company's headquarters are located in Lexington, Massachusetts, and it maintains a focus on advancing immuno-oncology research and development. Agenus est l'une des entreprises les plus populaires sur Eulerpool.